Processed Amniotic Fluid

An advancement in regenerative medicine utilizing minimally manipulated amniotic fluid, PalinGen® InovoFlo™ is a human allograft comprised of amniotic fluid components intended for homologous use to supplement tissue for protection, cushioning and lubrication.

Amniotic fluid functions as a supportive cushion to the fetus and provides a protective environment including rich sources of nutrients, cytokines and growth factors that are required for fetal development and maturation¹. Amnio Technology’s proprietary process preserves the original relevant characteristics of the amniotic fluid.

Amniotic fluid possesses anti-inflammatory, anti-microbial and regenerative properties that make it attractive for use in clinical applications².

Components in PalinGen® InovōFlo™ include:

  • Fibroblast Growth Factor (FGF)
  • Epidermal Growth Factor (EGF)
  • Platelet Derived Growth Factor (PDGF) A & B
  • Vascular Endothelial Growth Factor (VEGF)
  • Transforming Growth Factor beta (TGF-β)
  • Hyaluronic Acid (HA)
  • Interleukin-1 Receptor Antagonist (IL-1Ra)
  • Tissue Inhibitor of Metalloproteinases 1 (TIMP-1)
  • Tissue Inhibitor of Metalloproteinases 2 (TIMP-2)

Item number         Volume

 

IF-060025                0.25 cc

IF-060050                0.50 cc

IF-060100                1.0 cc

IF-060200                2.0 cc

 

Donor tissue is recovered using one of the safest recovery techniques and sterile equipment to minimize any bioburden contamination. Amniotic tissues are procured through a network of qualified and trained recovery partners, following stringent screening and recovery protocols in a highly controlled processing environment. All tissues are processed aseptically.
Safety
Communicable disease testing is performed by an FDA registered and Clinical Laboratory Improvement Amendments (CLIA Certified) laboratory. Donor blood sample is taken prior to or at the time of recovery and tested for HBsAg, HBcAb, HCVAb, HIV1/2 Ab, HCV NAT, HIV NAT, HBV NAT, RPR/STS, WNV, and HTLV I/II. Allografts are subjected to stringent USP testing prior to release.

References
1) Collection and characterization of amniotic fluid from scheduled C-section deliveries. Jan Pierce, Pam Jacobson, Eric Benedetti, et al. Cell Tissue Bank. 2016; 17: 413-425
2) Amniotic Fluid: Not Just Fetal Urine Anymore. Mark A Underwood, William M Gilbert, Michael P Sherman. Journal of Perinatology. 2005; 25: 341-348